ICAD INC. - COMMON STO

iCAD and Google Health Ink Strategic Development and Commercialization Agreement

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Positive New Research Presented at RSNA 2022 Reaffirms iCAD’s Breast AI Suite Improves Radiologists’ Performance and Breast Cancer Detection

21 Nov 2022 07:00:33 By Nasdaq GlobeNewswire

iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

15 Nov 2022 15:13:15 By Nasdaq GlobeNewswire

iCAD to Present at HLTH 2022 With Google

14 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

iCAD Reports Financial Results for Third Quarter Ended September 30, 2022

10 Nov 2022 15:03:15 By Nasdaq GlobeNewswire

iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice

10 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

27 Oct 2022 07:40:03 By Nasdaq GlobeNewswire

iCAD and Solis Mammography Ink Deal to Collaborate on Use of AI to Evaluate Risk of Cardiovascular Disease

11 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model

29 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

iCAD Reports Financial Results For Second Quarter 2022

10 Aug 2022 15:07:50 By Nasdaq GlobeNewswire

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

27 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

13 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series

29 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk

07 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022

06 Jun 2022 07:08:21 By Nasdaq GlobeNewswire

iCAD Announces CFO Transition

25 May 2022 07:01:43 By Nasdaq GlobeNewswire

New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography

18 May 2022 07:00:01 By Nasdaq GlobeNewswire

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

16 May 2022 07:00:02 By Nasdaq GlobeNewswire

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

11 May 2022 15:07:23 By Nasdaq GlobeNewswire